Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
22 results
- D1.524 - StingReady: a safe and alternative method for controlled sting challenge tests
- D1.515 - Occupational Exposure of Patients Allergic to Hymenoptera Venom
- D1.516 - Compliance with hymenoptera venom inmunotherapy (VIT)
- D1.517 - Adverse Reactions to Insect Venom Immunotherapy in a Reference Center
- D1.518 - Patient Phenotypes in Prolonged Immunotherapy for Hymenoptera Venom
- D1.519 - Safety of ultra-rush protocols in venom immunotherapy: a systematic review and meta-analysis of Portuguese data
- D1.520 - Immunological modulation during Apis mellifera venom immunotherapy
- D1.522 - Efficacy of hymenoptera venom immunotherapy in Portugal: a systematic review
- D1.523 - Clinical characterization of patients with Hymenoptera venom allergy undergoing venom immunotherapy stratified by basal serum tryptase
- D1.525 - Implementation of allergen-specific immunotherapy for insect allergy
D1.526 - Epidemiologic Characteristics of Hymenoptera Venom Allergic Patients from Two Different Environmental Areas
- D1.527 - Low tryptase and combined IgE biomarkers have limited predictive value in children with severe honeybee venom anaphylaxis
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?
D2.461 - Endothelial related miRs are dysregulated in C1-INH Angioedema patients: new potential biomarkers and therapeutic targets
D2.462 - Safety and predictors of tolerance in rituximab hypersensitivity management
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download